In Vitro and In Vivo Induction of a Th Cell Response Toward Peptides of the Melanoma-Associated Glycoprotein 100 Protein Selected by the TEPITOPE Program1
暂无分享,去创建一个
L Raddrizzani | M. Zöller | L. Raddrizzani | J. Hammer | M Zöller | O. Christ | B. Cochlovius | J Hammer | B Cochlovius | M Stassar | O Christ | I Mytilineos | M. Stassar | Björn Cochlovius | Marike Stassar | Ioannis Mytilineos | Margot Zöller
[1] M. Salgaller,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. , 1995, Cancer research.
[2] M. Eaman. Immune system. , 2000, Nursing standard (Royal College of Nursing (Great Britain) : 1987).
[3] C. Figdor,et al. Melanocyte lineage-specific antigen gp100 is recognized by melanoma- derived tumor-infiltrating lymphocytes , 1994, The Journal of experimental medicine.
[4] K. Sakaguchi,et al. Identification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 alleles. , 1998, Journal of immunology.
[5] F. Oesch,et al. Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals , 1996, Melanoma research.
[6] C. Wilson,et al. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. , 1998, Journal of immunology.
[7] F. Marincola,et al. Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy. , 1996, Journal of immunology.
[8] Steven A. Rosenberg,et al. Identification of a MHC Class II-Restricted Human gp100 Epitope Using DR4-IE Transgenic Mice , 2000, The Journal of Immunology.
[9] A. Sette,et al. Identification of GP100‐derived, melanoma‐specific cytotoxic T‐lymphocyte epitopes restricted by HLA‐A3 supertype molecules by primary in vitro immunization with peptide‐pulsed dendritic cells , 1998, International journal of cancer.
[10] O. de Backer,et al. A new family of genes coding for an antigen recognized by autologous cytolytic T lymphocytes on a human melanoma , 1995, The Journal of experimental medicine.
[11] J. Zeuthen,et al. The Immunogenic Properties of Melanoma-Associated Antigens Recognized by Cytotoxic T Lymphocytes , 1998, Experimental and Clinical Immunogenetics.
[12] U. Şahin,et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.
[13] O. Olerup,et al. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. , 1992, Tissue antigens.
[14] R. Steinman,et al. Antigen processing for amateurs and professionals. , 1998, Trends in cell biology.
[15] I. Stratford,et al. Targeting gene therapy to cancer: a review. , 1997, Oncology research.
[16] T. Boon. Toward a genetic analysis of tumor rejection antigens. , 1992, Advances in cancer research.
[17] P. Bruggen,et al. Tumor antigens recognized by T lymphocytes. , 1994, Annual review of immunology.
[18] R. Offringa,et al. Immunotherapy of cancer by peptide-based vaccines for the induction of tumor-specific T cell immunity. , 1996, Immunotechnology : an international journal of immunological engineering.
[19] D. Cassell,et al. Two roles for CD4 cells in the control of the generation of cytotoxic T lymphocytes. , 1991, Journal of immunology.
[20] P. Matzinger,et al. A fail-safe mechanism for maintaining self-tolerance , 1992, The Journal of experimental medicine.
[21] R. Gonin,et al. Retrovirus-mediated gene transfer of B7-1 and MHC class II converts a poorly immunogenic neuroblastoma into a highly immunogenic one. , 1996, Human gene therapy.
[22] H. Schreiber,et al. Active immunization against cancer cells: impediments and advances. , 1998, Seminars in oncology.
[23] U. Grohmann,et al. Dendritic cells, interleukin 12, and CD4+ lymphocytes in the initiation of class I-restricted reactivity to a tumor/self peptide. , 1998, Critical reviews in immunology.
[24] A. Sidoli,et al. Cutting edge: identification of novel T cell epitopes in Lol p5a by computational prediction. , 1999, Journal of immunology.
[25] C. Melief,et al. Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors , 1998, The Journal of experimental medicine.
[26] D. Schadendorf,et al. Dendritic cells generated from peripheral blood transfected with human tyrosinase induce specific T cell activation , 1995, European journal of immunology.
[27] D. Pardoll,et al. The role of CD4+ T cell responses in antitumor immunity. , 1998, Current opinion in immunology.
[28] J. Roth,et al. Gene therapy for cancer: what have we done and where are we going? , 1997, Journal of the National Cancer Institute.
[29] M F del Guercio,et al. Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.
[30] C. Lowenstein,et al. The Central Role of CD4+ T Cells in the Antitumor Immune Response , 1998, The Journal of experimental medicine.
[31] V. Brusic,et al. Melan-A/MART-151–73 represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4+ T cells , 2000 .
[32] Dirk Schadendorf,et al. Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells , 1998, Nature Medicine.
[33] Edgar G. Engleman,et al. Vaccination of patients with B–cell lymphoma using autologous antigen–pulsed dendritic cells , 1996, Nature Medicine.
[34] F. Sallusto,et al. Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.
[35] Antonio Lanzavecchia,et al. Universally immunogenic T cell epitopes: promiscuous binding to human MHC class II and promiscuous recognition by T cells , 1989, European journal of immunology.
[36] G. Mor,et al. Plasmid DNA: a new era in vaccinology. , 1998, Biochemical pharmacology.
[37] M. Colombo,et al. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo , 1996, The Journal of experimental medicine.
[38] A. Amoroso,et al. Peptide‐specific ctl in tumor‐infiltrating lymphocytes from metastatic melanomas expressing mart‐1/melan‐a, gp100 and tyrosinase genes: A study in an unselected group of hla‐a2.1‐positive patients , 1995, International journal of cancer.
[39] M. Shurin. Dendritic cells presenting tumor antigen , 1996, Cancer Immunology, Immunotherapy.
[40] H. Seigler,et al. Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA‐106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice , 1998, Journal of surgical oncology.
[41] M. Maio,et al. Immunogenicity of the ALLAVGATK (gp10017 – 25) peptide in HLA‐A3.1 melanoma patients , 1998, European journal of immunology.
[42] S. Levy,et al. Cytotoxic T cell responses to DNA vaccination: dependence on antigen presentation via class II MHC. , 1998, Journal of immunology.
[43] D. Bigner,et al. Bone Marrow–generated Dendritic Cells Pulsed with Tumor Extracts or Tumor RNA Induce Antitumor Immunity against Central Nervous System Tumors , 1997, The Journal of experimental medicine.
[44] J. Kirkwood,et al. New treatment options for patients with melanoma: review of melanoma-derived T-cell epitope-based peptide vaccines , 1996, Melanoma research.
[45] M. Lotze,et al. Bone marrow‐derived dendritic cells pulsed with a tumor‐specific peptide elicit effective anti‐tumor immunity against intracranial neoplasms , 1998, International journal of cancer.
[46] J. Peters,et al. Dendritic cells differentiated from human monocytes through a combination of IL-4, GM-CSF and IFN-gamma exhibit phenotype and function of blood dendritic cells. , 1995, Advances in experimental medicine and biology.
[47] M. Lotze,et al. Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pulsed with Synthetic or Natural Tumor Peptides Elicit Tumor‐Specific CTLs In Vitro , 1998, Journal of immunotherapy.
[48] O. de Backer,et al. Genes coding for tumor-specific rejection antigens. , 1994, Cold Spring Harbor symposia on quantitative biology.
[49] C. Figdor,et al. Identification of a novel peptide derived from the melanocyte‐specific gp100 antigen as the dominant epitope recognized by an HLA‐A2.1‐restricted anti‐melanoma CTL line , 1995, International journal of cancer.
[50] W. Kwok,et al. Human Class II Major Histocompatibility Complex Gene Transfer into Murine Neuroblastoma Leads to Loss of Tumorigenicity, Immunity Against Subsequent Tumor Challenge, and Elimination of Microscopic Preestablished Tumors , 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.
[51] H. Rammensee,et al. Peptides naturally presented by MHC class I molecules. , 1993, Annual review of immunology.
[52] A. Sette,et al. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. , 1995, Journal of immunology.
[53] E. Jaffee,et al. Cancer Vaccines , 1997, Current protocols in human genetics.
[54] H. Zarour,et al. The majority of autologous cytolytic T-lymphocyte clones derived from peripheral blood lymphocytes of a melanoma patient recognize an antigenic peptide derived from gene Pmel17/gp100. , 1996, The Journal of investigative dermatology.
[55] S. Ostrand-Rosenberg,et al. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. , 1994, Cellular immunology.
[56] C. Figdor,et al. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro. , 1995, Cancer research.
[57] C.-H. Chen,et al. Experimental vaccine strategies for cancer immunotherapy. , 1998, Journal of biomedical science.
[58] M. Moser,et al. Vaccination with tumor-antigen-pulsed dendritic cells induces in vivo resistance to a B cell lymphoma. , 1993, Advances in experimental medicine and biology.
[59] L. Adorini,et al. Dendritic cells are the most efficient in presenting endogenous naturally processed self-epitopes to class II-restricted T cells. , 1995, Journal of immunology.
[60] Rongfang Wang. Tumor Antigens Discovery: Perspectives for Cancer Therapy , 1997, Molecular medicine.
[61] J. Roder,et al. Improved engraftment of human tumours in SCID mice pretreated with radiation and anti-asialo GM1. , 1994, Anticancer research.
[62] L. Wysocki,et al. "Panning" for lymphocytes: a method for cell selection. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[63] F. Marincola,et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma , 1998, Nature Medicine.
[64] G. Hämmerling,et al. Alloreactive cytolytic T-cell clones preferentially recognize conformational determinants on histocompatibility antigens: analysis with genetically engineered hybrid antigens. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[65] J. Zeuthen,et al. Melanoma‐associated antigens recognized by cytotoxic T lymphocytes , 1998, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.
[66] M. Zöller,et al. Recombinant gp100 protein presented by dendritic cells elicits a T‐helper‐cell response in vitro and in vivo , 1999, International journal of cancer.
[67] F. Sinigaglia,et al. HLA class II peptide binding specificity and autoimmunity. , 1997, Advances in immunology.
[68] M. Zöller,et al. Human melanoma therapy in the SCID mouse: In vivo targeting and reactivation of melanoma‐specific cytotoxic T cells by bi‐specific antibody fragments , 1999, International journal of cancer.
[69] D. Weiner,et al. Modulating the immune response to genetic immunization , 1998, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[70] J. Sidney,et al. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. , 1997, Journal of immunology.
[71] Thomas Halder,et al. Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells , 1998, Cancer Immunology, Immunotherapy.
[72] W. Storkus,et al. B 7 Cost imulat ion , and T Helper Cell 1-associated Cytokines , 2003 .
[73] S. Rosenberg,et al. Immunobiology of human melanoma antigens MART-1 and gp100 and their use for immuno-gene therapy. , 1997, International reviews of immunology.
[74] Matteo Bellone,et al. Melanoma Cells Present a MAGE-3 Epitope to CD4+ Cytotoxic T Cells in Association with Histocompatibility Leukocyte Antigen DR11 , 1999, The Journal of experimental medicine.
[75] V. Brusic,et al. Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[76] E. Gilboa,et al. Regression of tumors in mice vaccinated with professional antigen‐presenting cells pulsed with tumor extracts , 1997, International journal of cancer.
[77] O RAJKA,et al. [TUMOR IMMUNOLOGY]. , 1963, Orvosi hetilap.
[78] T. Boon,et al. Tumor antigens recognized by T lymphocytes , 1997, International journal of clinical & laboratory research.